Related Experiment Video
Updated: Aug 31, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
A third mode of integrin antagonism
1Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877, USA.
Through the biochemical dissection of conformational changes, Shimaoka et al. (this issue of Immunity) have delineated a novel role for the I-like domain in the allosteric regulation of LFA-1 function and signaling. This work advances our understanding of LFA-1 antagonism and reveals new avenues for approaching LFA-1, and potentially other I-domain containing integrins, as drug targets.
Through the biochemical dissection of conformational changes, Shimaoka et al. (this issue of Immunity) have delineated a novel role for the I-like domain in the allosteric regulation of LFA-1 function and signaling. This work advances our understanding of LFA-1 antagonism and reveals new avenues for approaching LFA-1, and potentially other I-domain containing integrins, as drug targets.
Related Concept Videos
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Intracellular Signaling Affects Focal Adhesions
Some...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with one...
Anchoring Junctions

